Guardant Health rises as investors weigh strong growth outlook against patent overhang

Guardant Health (GH) is up 3.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to continued confidence in Guardant Health’s growth story after a strong second quarter and higher 2026 guidance, while investors also seem to be viewing the company’s recent patent case update as less damaging than initially feared. This could also reflect a rebound as the market reassesses the litigation risk after management said key current products are excluded from the royalty order and that collection is stayed pending appeal.

Details:

Guardant Health reported second-quarter 2026 revenue growth of 44% to $335.0 million, with strong contributions from both oncology and screening.

The company raised its 2026 revenue outlook to $1.34 billion to $1.36 billion, a sign that demand trends remained strong into the second half of the year.

In its August 24 appeal announcement, Guardant said the current versions of Shield and Guardant Reveal are excluded from the final district court order, and that Guardant360 design changes were validated to avoid ongoing royalty impact.

Analyst sentiment has remained constructive since the July earnings release, with several firms lifting price targets in early August, which likely helped support the stock despite the legal dispute.

Sources:

Guardant Health Investor Relations, SEC, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$GH Insider Trading Activity

$GH insiders have traded $GH stock on the open market 77 times in the past 6 months. Of those trades, 1 have been purchases and 76 have been sales.

Here’s a breakdown of recent trading of $GH stock by insiders over the last 6 months:

AMIRALI TALASAZ (Co-Chief Executive Officer) has made 0 purchases and 22 sales selling 557,500 shares for an estimated $73,748,728.
CHRIS FREEMAN (Chief Commercial Officer) has made 0 purchases and 5 sales selling 88,011 shares for an estimated $13,682,471.
HELMY ELTOUKHY (Co-Chief Executive Officer) has made 0 purchases and 7 sales selling 100,000 shares for an estimated $12,629,968.
TERILYN J. MONROE (Chief People Officer) has made 0 purchases and 6 sales selling 50,132 shares for an estimated $8,000,367.
KUMUD KALIA (Chief Information Officer) has made 1 purchase buying 600 shares for an estimated $78,456 and 6 sales selling 49,618 shares for an estimated $5,067,010.
JOHN G. SAIA (Chief Legal Officer) has made 0 purchases and 5 sales selling 30,000 shares for an estimated $3,381,064.
IAN T CLARK has made 0 purchases and 3 sales selling 21,056 shares for an estimated $2,988,499.
MEGHAN V. JOYCE has made 0 purchases and 4 sales selling 10,000 shares for an estimated $1,269,808.
STEVE E. KROGNES sold 9,294 shares for an estimated $1,231,521
MEDINA MANUEL HIDALGO has made 0 purchases and 7 sales selling 5,250 shares for an estimated $662,122.
MICHAEL BRIAN BELL (Chief Financial Officer) has made 0 purchases and 2 sales selling 5,000 shares for an estimated $518,351.
MUSA TARIQ has made 0 purchases and 7 sales selling 2,879 shares for an estimated $359,712.
MYRTLE S POTTER sold 1,556 shares for an estimated $204,084

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive GH Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$GH Hedge Fund Activity

We have seen 350 institutional investors add shares of $GH stock to their portfolio, and 257 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BLACKROCK, INC. removed 3,930,824 shares (-34.0%) from their portfolio in Q2 2026, for an estimated $589,741,524
BAILLIE GIFFORD & CO removed 2,605,899 shares (-53.3%) from their portfolio in Q2 2026, for an estimated $390,963,026
PIER 88 INVESTMENT PARTNERS LLC removed 2,050,800 shares (-99.7%) from their portfolio in Q2 2026, for an estimated $307,681,524
JANE STREET GROUP, LLC added 1,778,641 shares (+37031.9%) to their portfolio in Q2 2026, for an estimated $266,849,509
AMERIPRISE FINANCIAL INC added 1,736,011 shares (+122.7%) to their portfolio in Q2 2026, for an estimated $260,453,730
FMR LLC added 1,372,191 shares (+33.3%) to their portfolio in Q2 2026, for an estimated $205,869,815
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 1,311,320 shares (+inf%) to their portfolio in Q2 2026, for an estimated $196,737,339

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$GH Price Targets

Multiple analysts have issued price targets for $GH recently. We have seen 14 analysts offer price targets for $GH in the last 6 months, with a median target of $175.0.

Here are some recent targets:

Shannon O'Callaghan from Morgan Stanley set a target price of $175.0 on 07/09/2026
Patrick Donnelly from Citigroup set a target price of $215.0 on 07/08/2026
Michael Ryskin from B of A Securities set a target price of $190.0 on 07/06/2026
Vijay Kumar from Evercore ISI Group set a target price of $200.0 on 07/06/2026
Eve Burstein from Bernstein set a target price of $200.0 on 07/02/2026
Mark Massaro from BTIG set a target price of $190.0 on 07/01/2026
Subbu Nambi from Guggenheim set a target price of $160.0 on 06/29/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.